The report for Global Osteoporosis Drugs Market of Market Research
Future comprises extensive primary research along with the detail analysis of qualitative as
well as quantitative aspects by various industry experts, key opinion leaders to gain the
deeper insight of the market and industry performance. Osteoporosis is weakening of bones
due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and
subsequent higher risk of a broken fracture. It generally occurs at an advanced age and
women are more susceptible to it than males by about three to four folds. WHO estimates
that around 1.66 million hip fractures occur each year worldwide due to osteoporosis.
According to national osteoporosis foundation about 54 million Americans suffer from
osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The
disease prevalence is lowest in African population.
The market driving factors were identified to be rise in the geriatric population, increased
screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and
focus towards female health, rising prevalence of diseases, conditions and medical
procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia,
hormonal disorders, modern lifestyle etc.
The market restraints are loss of patents of block busters, greater penetration of generics
and fragmentation of market, poor efficacy and side effects of present therapies, non-life
threatening nature and poor symptoms of osteoporosis etc.
Taking all the factors into consideration, we expect the Global Osteoporosis Market which
totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.
Study Objectives Global Osteoporosis Drugs Market:
To provide detail analysis of the market structure along with forecast for the next 7
years of the various segments and sub-segments of the Global Osteoporosis Drugs
Market
To provide insights about factors affecting the market growth
To analyze the market based on various factors- price analysis, supply chain
analysis, porters five force analysis etc.
To provide historical and forecast revenue of the market segments and sub-
segments with respect to four main geographies and their countries- Americas,
Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market
size and future prospective
To provide country level analysis of the market for segments by drug class
(bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS),
parathyroid hormone (PTH) and others), by route of administration (oral, injectable
and others) and by gender (male, female and children).
To provide overview of key players and their strategic profiling in the market,
comprehensively analyzing their core competencies, and drawing a competitive
landscape for the market
To track and analyze competitive developments such as joint ventures, strategic
alliances, mergers and acquisitions, new product developments, and research and
developments globally.